Madison Elsaadi
Stock Analyst at B. Riley Securities
(4.80)
# 489
Out of 4,509 analysts
52
Total ratings
70%
Success rate
57.5%
Average return
Main Sectors:
Stocks Rated by Madison Elsaadi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $160 | $48.38 | +230.72% | 1 | Jul 13, 2026 | |
| ETON Eton Pharmaceuticals | Reiterated: Buy | $40 | $37.34 | +7.12% | 14 | Jun 25, 2026 | |
| IRD Opus Genetics | Maintained: Buy | $9 → $10 | $3.81 | +162.47% | 2 | Apr 30, 2026 | |
| WVE Wave Life Sciences | Rated: Buy | $37 → $31 | $5.95 | +421.01% | 14 | Apr 30, 2026 | |
| CMPS COMPASS Pathways | Initiated Coverage: Buy | $17 | $13.19 | +28.93% | 1 | Apr 24, 2026 | |
| CAPR Capricor Therapeutics | Rated: Buy | $50 → $63 | $20.61 | +205.68% | 6 | Mar 13, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $5 | $2.43 | +105.76% | 3 | Mar 10, 2026 | |
| VNDA Vanda Pharmaceuticals | Maintained: Buy | $14 → $17 | $6.00 | +183.33% | 4 | Feb 25, 2026 | |
| FENC Fennec Pharmaceuticals | Initiated Coverage: Buy | $16 | $10.75 | +48.84% | 1 | Feb 12, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintained: Buy | $61 → $101 | $74.11 | +36.28% | 4 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $179 | $228.28 | -21.59% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $6.12 | n/a | 1 | Jan 23, 2025 |
Spruce Biosciences
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $160
Current: $48.38
Upside: +230.72%
Eton Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $40
Current: $37.34
Upside: +7.12%
Opus Genetics
Apr 30, 2026
Maintained: Buy
Price Target: $9 → $10
Current: $3.81
Upside: +162.47%
Wave Life Sciences
Apr 30, 2026
Rated: Buy
Price Target: $37 → $31
Current: $5.95
Upside: +421.01%
COMPASS Pathways
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $13.19
Upside: +28.93%
Capricor Therapeutics
Mar 13, 2026
Rated: Buy
Price Target: $50 → $63
Current: $20.61
Upside: +205.68%
Ovid Therapeutics
Mar 10, 2026
Reiterated: Buy
Price Target: $5
Current: $2.43
Upside: +105.76%
Vanda Pharmaceuticals
Feb 25, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $6.00
Upside: +183.33%
Fennec Pharmaceuticals
Feb 12, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $10.75
Upside: +48.84%
Arrowhead Pharmaceuticals
Jan 22, 2026
Maintained: Buy
Price Target: $61 → $101
Current: $74.11
Upside: +36.28%
Oct 1, 2025
Initiated Coverage: Buy
Price Target: $179
Current: $228.28
Upside: -21.59%
Jan 23, 2025
Reiterated: Buy
Price Target: $11
Current: $6.12
Upside: n/a